| __timestamp | BioCryst Pharmaceuticals, Inc. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 165772000 |
| Thursday, January 1, 2015 | 13047000 | 196614000 |
| Friday, January 1, 2016 | 11253000 | 303251000 |
| Sunday, January 1, 2017 | 13933000 | 366406000 |
| Monday, January 1, 2018 | 29514000 | 434407000 |
| Tuesday, January 1, 2019 | 37121000 | 468711000 |
| Wednesday, January 1, 2020 | 67929000 | 516922000 |
| Friday, January 1, 2021 | 118818000 | 739560000 |
| Saturday, January 1, 2022 | 159371000 | 1002140000 |
| Sunday, January 1, 2023 | 213894000 | 1161300000 |
| Monday, January 1, 2024 | 1242157000 |
Infusing magic into the data realm
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Over the past decade, Incyte Corporation and BioCryst Pharmaceuticals, Inc. have demonstrated distinct approaches to managing Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Incyte's SG&A expenses surged by approximately 600%, peaking at over $1.16 billion in 2023. This reflects a strategic investment in expanding their market presence and operational capabilities. In contrast, BioCryst's SG&A expenses grew by nearly 280% during the same period, reaching $214 million in 2023. This indicates a more conservative approach, possibly focusing on targeted growth and cost efficiency. The data highlights the divergent paths these companies have taken in their quest for market leadership, offering valuable insights into their operational priorities and financial health.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Incyte Corporation
BeiGene, Ltd. or Incyte Corporation: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Incyte Corporation and Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Insmed Incorporated or BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared